Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,943,906
+$1,127,152 QoQ
Shares Held
35,727
+87.6% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#269
of 751 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026&PARTNERS holds $32,580,374 across 34 Biotechnology names. EXEL ranks #3 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
25,535 | $12,684,000 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,467 | $3,408,893 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
35,727 | $1,943,906 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
5,994 | $1,467,151 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3,203 | $964,199 | |
| 6 | ARGX |
Argenx SE
|
1,000 | $927,770 | |
| 7 | TECH |
BIO-TECHNE Corp
|
12,729 | $899,303 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
11,335 | $887,190 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,943,906 | 35,727 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $816,754 | 19,043 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $623,131 | 14,217 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $585,923 | 14,187 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $813,143 | 18,447 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $821,026 | 22,238 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $226,639 | 6,806 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||